Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

MOTS-c cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established MOTS-c cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. The CB4211 phase 1 study (a different molecule) used single administration in the first part, 7 days in the multiple-dose part and 28 days in the fatty liver disease part 9.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • MOTS-c combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established MOTS-c cycle length?
No. Human studies administered MOTS-c for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of MOTS-c?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
MOTS-c dosing reference Full research page

References

  1. Drugs@FDA application data queried through openFDA for MOTS-c (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  2. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, questions and briefing documents) FDA Advisory Committee Calendar. 2026
  3. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 (covering BPC-157-, KPV-, TB-500-, MOTS-c-, Emideltide-, Epitalon- and Semax-related bulk drug substances) FDA. 2026
  4. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  5. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance Cell Metab. 2015
  6. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation Front Endocrinol (Lausanne). 2023
  7. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis Nat Commun. 2021
  8. PubChem compound record for MOTS-c (CID 146675088; CAS 1627580-64-6) PubChem. 2026
  9. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (NCT03998514), completed, no posted results ClinicalTrials.gov. 2021